J&J's TREMFYA Receives FDA Approval For Moderately To Severely Active Ulcerative Colitis In Adults
12/9 03:01
(RTTNews) - Johnson & Johnson (JNJ) said that the U.S. Food and Drug Administration has approved TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine in which the lining of the colon...